Novel therapies for hepatitis C — one pill fits all?
- 28 June 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 12 (8), 595-610
- https://doi.org/10.1038/nrd4050
Abstract
Almost 25 years after the hepatitis C virus (HCV) was identified, and following intense research and development efforts, a large number of direct-acting antiviral drugs are now beginning to reach patient care. Accordingly, the way in which care is delivered is evolving at a breath-taking pace. Here, we review the current and upcoming treatment options for HCV, describe the key challenges facing clinicians and drug developers and discuss how the landscape in the HCV arena will change over the coming years.Keywords
This publication has 117 references indexed in Scilit:
- Chronic hepatitis C virus (HCV) disease burden and cost in the United StatesHepatology, 2012
- Three-Dimensional Architecture and Biogenesis of Membrane Structures Associated with Hepatitis C Virus ReplicationPLoS Pathogens, 2012
- Suppression of Viral RNA Binding and the Assembly of Infectious Hepatitis C Virus Particles In Vitro by Cyclophilin InhibitorsJournal of Virology, 2012
- Discovering the first microRNA-targeted drugThe Journal of cell biology, 2012
- Hepatitis C virus host cell entryCurrent Opinion in Virology, 2012
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1New England Journal of Medicine, 2012
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus InfectionScience, 2010
- GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796Antimicrobial Agents and Chemotherapy, 2009
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005